122 related articles for article (PubMed ID: 24685766)
1. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.
Schuemie MJ; Trifirò G; Coloma PM; Ryan PB; Madigan D
Stat Methods Med Res; 2016 Dec; 25(6):2577-2592. PubMed ID: 24685766
[TBL] [Abstract][Full Text] [Related]
2. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.
Suchard MA; Zorych I; Simpson SE; Schuemie MJ; Ryan PB; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S83-93. PubMed ID: 24166226
[TBL] [Abstract][Full Text] [Related]
3. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.
Norén GN; Bergvall T; Ryan PB; Juhlin K; Schuemie MJ; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S107-21. PubMed ID: 24166228
[TBL] [Abstract][Full Text] [Related]
4. Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases.
Whalen E; Hauben M; Bate A
Drug Saf; 2018 Jun; 41(6):565-577. PubMed ID: 29468602
[TBL] [Abstract][Full Text] [Related]
5. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
[TBL] [Abstract][Full Text] [Related]
6. Using Rich Data on Comorbidities in Case-Control Study Design with Electronic Health Record Data Improves Control of Confounding in the Detection of Adverse Drug Reactions.
Backenroth D; Chase H; Friedman C; Wei Y
PLoS One; 2016; 11(10):e0164304. PubMed ID: 27716785
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the empirical performance of methods for a risk identification system.
Ryan PB; Stang PE; Overhage JM; Suchard MA; Hartzema AG; DuMouchel W; Reich CG; Schuemie MJ; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S143-58. PubMed ID: 24166231
[TBL] [Abstract][Full Text] [Related]
8. Evaluating performance of risk identification methods through a large-scale simulation of observational data.
Ryan PB; Schuemie MJ
Drug Saf; 2013 Oct; 36 Suppl 1():S171-80. PubMed ID: 24166233
[TBL] [Abstract][Full Text] [Related]
9. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
[TBL] [Abstract][Full Text] [Related]
10. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods.
Schuemie MJ; Coloma PM; Straatman H; Herings RM; Trifirò G; Matthews JN; Prieto-Merino D; Molokhia M; Pedersen L; Gini R; Innocenti F; Mazzaglia G; Picelli G; Scotti L; van der Lei J; Sturkenboom MC
Med Care; 2012 Oct; 50(10):890-7. PubMed ID: 22929992
[TBL] [Abstract][Full Text] [Related]
11. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
Lin KJ; Schneeweiss S
Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
[TBL] [Abstract][Full Text] [Related]
12. Multiple self-controlled case series for large-scale longitudinal observational databases.
Simpson SE; Madigan D; Zorych I; Schuemie MJ; Ryan PB; Suchard MA
Biometrics; 2013 Dec; 69(4):893-902. PubMed ID: 24117144
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of disproportionality safety signaling applied to healthcare databases.
DuMouchel W; Ryan PB; Schuemie MJ; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S123-32. PubMed ID: 24166229
[TBL] [Abstract][Full Text] [Related]
14. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.
Ryan PB; Schuemie MJ; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S95-106. PubMed ID: 24166227
[TBL] [Abstract][Full Text] [Related]
15. Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database.
Zhou X; Douglas IJ; Shen R; Bate A
Drug Saf; 2018 May; 41(5):523-536. PubMed ID: 29327136
[TBL] [Abstract][Full Text] [Related]
16. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems.
Gosho M; Maruo K; Tada K; Hirakawa A
Eur J Clin Pharmacol; 2017 Jun; 73(6):779-786. PubMed ID: 28280890
[TBL] [Abstract][Full Text] [Related]
17. Predictive modeling of structured electronic health records for adverse drug event detection.
Zhao J; Henriksson A; Asker L; Boström H
BMC Med Inform Decis Mak; 2015; 15 Suppl 4(Suppl 4):S1. PubMed ID: 26606038
[TBL] [Abstract][Full Text] [Related]
18. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.
Reich CG; Ryan PB; Suchard MA
Drug Saf; 2013 Oct; 36 Suppl 1():S195-204. PubMed ID: 24166235
[TBL] [Abstract][Full Text] [Related]
19. Supervised signal detection for adverse drug reactions in medication dispensing data.
Hoang T; Liu J; Roughead E; Pratt N; Li J
Comput Methods Programs Biomed; 2018 Jul; 161():25-38. PubMed ID: 29852965
[TBL] [Abstract][Full Text] [Related]
20. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
